Octagon Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Octagon Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.8M	Buy	3,166,600 +543,000	+21%	+$5.18M	2.97%	15
2025 Q4	$31.9M	Sell	2,623,600 -400	-0%	-$4.86K	3.87%	9
2025 Q3	$30.7M	Buy	2,624,000 +199,000	+8%	+$2.38M	4.65%	6
2025 Q2	$22.5M	Hold	2,425,000	–	–	4.94%	7
2025 Q1	$17.8M	Hold	2,425,000	–	–	3.44%	8
2024 Q4	$20.7M	Hold	2,425,000	–	–	3.41%	11
2024 Q3	$21.1M	Hold	2,425,000	–	–	3.28%	10
2024 Q2	$16.6M	Hold	2,425,000	–	–	2.61%	12
2024 Q1	$22.1M	Buy	+2,425,000	New	+$17.2M	2.64%	10

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Octagon Capital Advisors's OCUL Position: Q1 2026 in Review

Octagon Capital Advisors increased its Ocular Therapeutix (OCUL) stake by 21% in Q1 2026, buying an estimated $5.18M and bringing the position to 3,166,600 shares worth $26.8M. The position accounts for 2.97% of the portfolio, ranked #15.

Octagon Capital Advisors first reported a position in OCUL in Q1 2024 and has held it in 9 quarters since. The position peaked at $31.9M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Octagon Capital Advisors held 3,166,600 shares of Ocular Therapeutix worth $26.8M as of Q1 2026.
Octagon Capital Advisors bought 543,000 Ocular Therapeutix shares in Q1 2026, an estimated $5.18M.
Ocular Therapeutix made up 2.97% of Octagon Capital Advisors's portfolio in Q1 2026, its #15 holding.
Octagon Capital Advisors first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 9 quarters since.
Octagon Capital Advisors's Ocular Therapeutix position peaked at $31.9M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.